Objective:

To evaluate the rate of remission induction and maintenance with tacrolimus (TAC) therapy in patients with ulcerative colitis (UC), along with associated factors, drug safety outcomes, and specific adverse events.

Approach:

Key Findings:

• The overall remission induction rate with TAC was approximately 50%.
• At 52 weeks, 51 patients maintained remission while 48 did not, indicating a significant relapse rate.
• Factors influencing remission included clinical history, previous biologic therapy, and endoscopic scores.

Interpretation:

Tacrolimus is effective for inducing remission in UC, but maintenance of remission remains a challenge, with significant relapse rates observed, necessitating further investigation into maintenance strategies.

Limitations:

• Retrospective design may introduce bias.
• Limited generalizability due to specific patient population and treatment protocols, along with potential confounding factors.

Conclusion:

Tacrolimus shows promise in managing UC, but further studies are needed to optimize maintenance strategies, minimize relapse rates, and explore the long-term safety of TAC therapy.

Source

Based on findings from:

Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance

Ayumi Ito, Shun Murasugi, Miki Koroku, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige, Yousuke Nakai. Bmc Gastroenterology, 2026.

https://link.springer.com/article/10.1186/s12876-026-04670-3

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.